SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Marcia D McNutt, Shuling Liu, Amita Manatunga, Erica B Royster, Charles L Raison, Bobbi J Woolwine, Marina F Demetrashvili, Andrew H Miller, Dominique L Musselman, Neurobehavioral Effects of Interferon-α in Patients with Hepatitis-C: Symptom Dimensions and Responsiveness to Paroxetine, Neuropsychopharmacology, 2012, 37, 6, 1444

    CrossRef

  2. 2
    Tohru Noguchi, Akihiro Tamori, Naoki Ogura, Yuji Hori, Satoru Ikeda, Shuhei Nishiguchi, Investigation of Interferon-α Response by a Single Amino Acid Substitution of Nonstructural Protein 5A in Hepatitis C Virus-Infected Patients, Journal of Interferon & Cytokine Research, 2011, 31, 8, 589

    CrossRef

  3. 3
    Xianfeng Li, Yong-Kang Zhang, Yang Liu, Charles Z. Ding, Yasheen Zhou, Qun Li, Jacob J. Plattner, Stephen J. Baker, Suoming Zhang, Wieslaw M. Kazmierski, Lois L. Wright, Gary K. Smith, Richard M. Grimes, Renae M. Crosby, Katrina L. Creech, Luz H. Carballo, Martin J. Slater, Richard L. Jarvest, Pia Thommes, Julia A. Hubbard, Maire A. Convery, Pamela M. Nassau, William McDowell, Tadeusz J. Skarzynski, Xuelei Qian, Dazhong Fan, Liang Liao, Zhi-Jie Ni, Lewis E. Pennicott, Wuxin Zou, Jon Wright, Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates, Bioorganic & Medicinal Chemistry Letters, 2010, 20, 19, 5695

    CrossRef

  4. 4
    Charles Z. Ding, Yong-Kang Zhang, Xianfeng Li, Yang Liu, Suoming Zhang, Yasheen Zhou, Jacob J. Plattner, Stephen J. Baker, Liang Liu, Maosheng Duan, Richard L. Jarvest, Jingjing Ji, Wieslaw M. Kazmierski, Matthew D. Tallant, Lois L. Wright, Gary K. Smith, Renae M. Crosby, Amy A. Wang, Zhi-Jie Ni, Wuxin Zou, Jon Wright, Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease, Bioorganic & Medicinal Chemistry Letters, 2010, 20, 24, 7317

    CrossRef

  5. 5
    Jason Grebely, Greg Dore, Kucers' The Use of Antibiotics Sixth Edition, 2010,

    CrossRef

  6. 6
    Dimitrios Dimitroulopoulos, Elefteria Petroulaki, Spilios Manolakopoulos, Olga Anagnostou, Domna Tsaklakidou, Dimitrios Xinopoulos, Klisthenis Tsamakidis, Dimitrios Tzourmakliotis, Emmanouel Paraskevas, Peginterferon/ribavirin treatment achieves a higher compliance rate than interferon/ribavirin combination in patients chronically infected with HCV on methadone maintenance, European Journal of Gastroenterology & Hepatology, 2009, 21, 12, 1407

    CrossRef

  7. 7
    Kyoung-Tae Kim, Sang-Young Han, Jong-Han Kim, Hyun-Ah Yoon, Yang-Hyun Baek, Min-Ji Kim, Sung-Wook Lee, Jin-Seok Jang, Jong-Hun Lee, Myung-Hwan Roh, Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C, The Korean Journal of Hepatology, 2008, 14, 1, 36

    CrossRef

  8. 8
    Tohru Noguchi, Tomoko Otsubaki, Izuru Ando, Naoki Ogura, Satoru Ikeda, Kunitada Shimotohno, Isolation and gene analysis of interferon α-resistant cell clones of the hepatitis C virus subgenome, Virology, 2008, 375, 2, 424

    CrossRef

  9. 9
    Benjamin Leader, Quentin J. Baca, David E. Golan, Protein therapeutics: a summary and pharmacological classification, Nature Reviews Drug Discovery, 2008, 7, 1, 21

    CrossRef

  10. 10
    Markus Backmund, Ansprechbarkeit von Drogengebrauchern über Infektionsrisiken für HIV und HCV, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2007, 50, 4, 471

    CrossRef

  11. 11
    Amrita Sethi, Mitchell L. Shiffman, Approach to the Management of Patients with Chronic Hepatitis C Who Failed to Achieve Sustained Virologic Response, Infectious Disease Clinics of North America, 2006, 20, 1, 115

    CrossRef

  12. 12
    Ming-Yang Lai, Combined Interferon and Ribavirin Therapy for Chronic Hepatitis C in Taiwan, Intervirology, 2006, 49, 1-2, 91

    CrossRef

  13. 13
    Jean-Michel Pawlotsky, Therapy of hepatitis C: From empiricism to eradication, Hepatology, 2006, 43, S1
  14. 14
    Zeid Kayali, Douglas R. LaBrecque, Warren N. Schmidt, Treatment of hepatitis C cryoglobulinemia: Mission and challenges, Current Treatment Options in Gastroenterology, 2006, 9, 6, 497

    CrossRef

  15. 15
    Amrita Sethi, Mitchell L. Shiffman, Approach to the Management of Patients with Chronic Hepatitis C Who Failed to Achieve Sustained Virologic Response, Clinics in Liver Disease, 2005, 9, 3, 453

    CrossRef

  16. 16
    Graham R. Foster, Abid R. Suddle, Treatment of HCV infection with pegylated interferons, Current Hepatitis Reports, 2005, 4, 2, 49

    CrossRef

  17. 17
    G. V. Papatheodoridis, E. Cholongitas, Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options, Journal of Viral Hepatitis, 2004, 11, 4
  18. 18
    M. Backmund, K. Meyer, B. R. Edlin, Infrequent Reinfection after Successful Treatment for Hepatitis C Virus Infection in Injection Drug Users, Clinical Infectious Diseases, 2004, 39, 10, 1540

    CrossRef

  19. 19
    N. C Tassopoulos, D. Tsantoulas, M. Raptopoulou, T. Vassiliadis, S. Kanatakis, E. Paraskevas, I. Vafiadis, A. Avgerinos, C. Tzathas, S. Manolakopoulos, I. Ketikoglou, P. Aggelis, K. Goritsas, G. Giannoulis, G. Hatzis G, K. Thomopoulos, E. Akriviadis, V. Sypsa, A. Hatzakis, A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1, Journal of Viral Hepatitis, 2003, 10, 3
  20. 20
    Jay H Hoofnagle, Challenges in therapy of chronic hepatitis B, Journal of Hepatology, 2003, 39, 230

    CrossRef

  21. 21
    Hidenori Toyoda, Takashi Kumada, Kazuhiko Hayashi, Takashi Honda, Kiyoshi Morita, Daisaku Nishimura, Kazumi Imada, Masami Imoto, Yuji Horiguchi, Hiroshi Nakano, Isao Nakano, Yoshihide Fukuda, Characteristics and prognosis of hepatocellular carcinoma detected in sustained responders to interferon therapy for chronic hepatitis C, Cancer Detection and Prevention, 2003, 27, 6, 498

    CrossRef

  22. 22
    Diana L. Sylvestre, Hepatitis C and Addiction, Journal of Maintenance in the Addictions, 2003, 2, 3, 7

    CrossRef

  23. 23
    Jean-Michel Pawlotsky, Hepatitis C virus genetic variability: pathogenic and clinical implications, Clinics in Liver Disease, 2003, 7, 1, 45

    CrossRef

  24. 24
    Stephen J Polyak, Hepatitis C virus–cell interactions and their role in pathogenesis, Clinics in Liver Disease, 2003, 7, 1, 67

    CrossRef

  25. 25
    MOSTAFA K EL-AWADY, MOHAMED M ABDEL RAHMAN, SOMAYIA M ISMAIL, KHALDA S AMR, MOATAZA OMRAN, SABRY A MOHAMED, Prediction of relapse after interferon therapy in hepatitis C virus-infected patients by the use of triple assay, Journal of Gastroenterology and Hepatology, 2003, 18, 1
  26. 26
    Todd E. Dantzler, Eric J. Lawitz, Treatment of chronic hepatitis C in nonresponders to previous therapy, Current Gastroenterology Reports, 2003, 5, 1, 78

    CrossRef

  27. 27
    Masao Omata, Yasushi Shiratori, Haruhiko Yoshida, Extracellular Matrix and the Liver, 2003,

    CrossRef

  28. 28
    Yasushi Shiratori, Haruhiko Yoshida, Masao Omata, Frontiers in Viral Hepatitis, 2003,

    CrossRef

  29. 29
    Nathaniel A. Brown, Frontiers in Viral Hepatitis, 2003,

    CrossRef

  30. 30
    Gianna Dal Molin, Filippo Ansaldi, Claudia Biagi, Pierlanfranco D'Agaro, Manola Comar, Lory Crocè, Claudio Tiribelli, Cesare Campello, Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy, Journal of Medical Virology, 2002, 68, 3
  31. 31
    Ayaz M Majid, David R Gretch, Current and future hepatitis C virus diagnostic testing: problems and advancements, Microbes and Infection, 2002, 4, 12, 1227

    CrossRef

  32. 32
    Paul J Pockros, Developments in the treatment of chronic hepatitis C, Expert Opinion on Investigational Drugs, 2002, 11, 4, 515

    CrossRef

  33. 33
    Robert J. Fontana, Steven M. Schwartz, Achamyeleh Gebremariam, Anna S.F. Lok, Cheryl A. Moyer, Emotional Distress During Interferon-α-2B and Ribavirin Treatment of Chronic Hepatitis C, Psychosomatics, 2002, 43, 5, 378

    CrossRef

  34. 34
    Khalid S.A. Khabar, Stephen J. Polyak, Hepatitis C Virus-Host Interactions: The NS5A Protein and the Interferon/Chemokine Systems, Journal of Interferon & Cytokine Research, 2002, 22, 10, 1005

    CrossRef

  35. 35
    Svetlozar N. Natov, Brian J. G. Pereira, Management of Hepatitis C Infection in Renal Transplant Recipients, American Journal of Transplantation, 2002, 2, 6
  36. 36
    Mitchell L. Shiffman, Retreatment of patients with chronic hepatitis C, Hepatology, 2002, 36, S1
  37. 37
    Hidenori Toyoda, Takashi Kumada, Takashi Honda, Kazuhiko Hayashi, Yoshiaki Katano, Isao Nakano, Tetsuo Hayakawa, Yoshihide Fukuda, Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2001, 16, 10
  38. 38
    George K. Koukoulis, Chronic hepatitis C: Grading, staging, and searching for reliable predictors of outcome, Human Pathology, 2001, 32, 9, 899

    CrossRef

  39. 39
    Jili A. Addesa, Victor J. Navarro, Concise review of the management of hepatitis C, Comprehensive Therapy, 2001, 27, 4, 275

    CrossRef

  40. You have free access to this content40
    Tohru Noguchi, Shinya Satoh, Takeshi Noshi, Eriko Hatada, Ryuji Fukuda, Akihiko Kawai, Satoru Ikeda, Makoto Hijikata, Kunitada Shimotohno, Effects of Mutation in Hepatitis C Virus Nonstructural Protein 5A on Interferon Resistance Mediated by Inhibition of PKR Kinase Activity in Mammalian Cells, Microbiology and Immunology, 2001, 45, 12
  41. 41
    Filippo Ansaldi, Francesco Torre, Bianca Marisa Bruzzone, Antonino Picciotto, Pietro Crovari, Giancarlo Icardi, Evaluation of a new hepatitis C virus sequencing assay as a routine method for genotyping, Journal of Medical Virology, 2001, 63, 1
  42. 42
    Trinidad Caballero, Alejandro Pérez-Milena, Marco Masseroli, Francisco O'Valle, Francisco J Salmerón, Raimundo M.G Del Moral, Guillermo Sánchez-Salgado, Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C, Journal of Hepatology, 2001, 34, 5, 740

    CrossRef

  43. 43
    Mitchell L. Shiffman, MANAGEMENT OF INTERFERON THERAPY NONRESPONDERS, Clinics in Liver Disease, 2001, 5, 4, 1025

    CrossRef

  44. 44
    E. Beth Devine, Kris V. Kowdley, David L. Veenstra, Sean D. Sullivan, Management Strategies for Ribavirin-Induced Hemolytic Anemia in the Treatment of Hepatitis C: Clinical and Economic Implications, Value in Health, 2001, 4, 5
  45. 45
    J Schinkel, A.C.M Kroes, M.J Wagtmans, C.B.H.W Lamers, B van Hoek, Monitoring response during a randomised controlled trial of escalating interferon dose for chronic hepatitis C infection: predictive value of quantitative and qualitative HCV RNA assays, Journal of Clinical Virology, 2001, 22, 1, 61

    CrossRef

  46. 46
    Moisés Diago, Dolores Suárez, Luis García-Villarreal, Angeles Castro, Agustín Domínguez, Margarita Pardo, Juan A. del Olmo, Francisco Pérez-Hernández, José Aguilar, Juan Antonio Quiroga, Vicente Carreño, Multicenter randomized study comparing initial daily induction with high dose lymphoblastoid interferon vs. standard interferon treatment for chronic hepatitis c, Journal of Medical Virology, 2001, 64, 4
  47. 47
    M. A. Feitelson, J. D. Larkin, New Animal Models of Hepatitis B and C, ILAR Journal, 2001, 42, 2, 127

    CrossRef

  48. 48
    Eiji Yano, Kazumi Tagawa, Kazue Yamaoka, Masaki Mori, Test validity of periodic liver function tests in a population of Japanese male bank employees, Journal of Clinical Epidemiology, 2001, 54, 9, 945

    CrossRef

  49. 49
    Richard A. Willson, The Benefit of Long-term Interferon Alfa Therapy for Symptomatic Mixed Cryoglobulinemia (Cutaneous Vasculitis/Membranoproliferative Glomerulonephritis) Associated With Chronic Hepatitis C Infection, Journal of Clinical Gastroenterology, 2001, 33, 2, 137

    CrossRef

  50. 50
    Ke-Qin Hu, John M. Vierling, Allan G. Redeker, Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection, Journal of Viral Hepatitis, 2001, 8, 1
  51. 51
    Guang-Bi Yao, Xi-Xian Fu, Geng-Shan Tian, Dao-Zhen Xu, Lian-Jie Hao, Yu-Shan Huangfu, Chun-Xin Su, A multicenter, randomized, controlled trial of interferon alfacon-1 compared with α-2a-interferon in Chinese patients with chronic hepatitis C virus infection, Journal of Gastroenterology and Hepatology, 2000, 15, 10
  52. 52
    Mitchell L. Shiffman, Scott B. Verbeke, Pamela M. Kimball, Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes, Antiviral Research, 2000, 48, 2, 91

    CrossRef

  53. 53
    Geoffrey C Farrell, Consensus among consensus conferences on management of hepatitis C: What we knew then and are still sure about, what we are newly sure about, and what we still need to know, Journal of Gastroenterology and Hepatology, 2000, 15,
  54. 54
    Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia–Pacific region1, Journal of Gastroenterology and Hepatology, 2000, 15, 8
  55. 55
    Mark P. Epstein, Tamsin Knox, Current views on hepatitis C virus infection, Current Infectious Disease Reports, 2000, 2, 1, 55

    CrossRef

  56. 56
    Yasushi Shiratori, Alan S. Perelson, Leor Weinberger, Fumio Imazeki, Osamu Yokosuka, Ryo Nakata, Masashi Ihori, Katsutaro Hirota, Naomi Ono, Hisamoto Kuroda, Teiji Motojima, Masaru Nishigaki, Masao Omata, Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta, Journal of Hepatology, 2000, 33, 2, 313

    CrossRef

  57. 57
    Fusao Ikeda, Hiroyuki Shimomura, Masanobu Miyake, Shin-Ichi Fujioka, Mamoru Itoh, Akira Takahashi, Yoshiaki Iwasaki, Kosaku Sakaguchi, Kazuhide Yamamoto, Toshihiro Higashi, Takao Tsuji, Early Clearance of Circulating Hepatitis C Virus Enhanced by Induction Therapy with Twice-a-Day Intravenous Injection of IFN-β, Journal of Interferon & Cytokine Research, 2000, 20, 9, 831

    CrossRef

  58. 58
    Fusao Ikeda, Hiroyuki Shimomura, Hiroshi Nakagawa, Yoshiaki Iwasaki, Masanobu Miyake, Hideyuki Tsuji, Shin-ichi Fukioka, Mamoru Itoh, Akira Takahashi, Takao Tsuji, Efficient Enhancement of Priming Effect by Intermittent Treatment with Interferon, Biochemical and Biophysical Research Communications, 2000, 278, 3, 599

    CrossRef

  59. 59
    Ming-Yang Lai, Firstline treatment for hepatitis C: combination interferon/ribavirin versus interferon monotherapy, Journal of Gastroenterology and Hepatology, 2000, 15,
  60. 60
    Steedman A. Sarbah, Zobair M. Younossi, Hepatitis C, Journal of Clinical Gastroenterology, 2000, 30, 2, 125

    CrossRef

  61. 61
    Anne Bastie, Laurent Castera, Francoise Roudot-Thoraval, Daniel Dhumeaux, Jean-Michel Pawlotsky, Inhibition of the cyclooxygenase/lipoxygenase pathways to improve interferon alfa efficacy in chronic hepatitis C: A wrong track, Hepatology, 2000, 31, 2
  62. 62
    Stany Depraetere, Els Van Kerschaever, Hans Van Vlierberghe, André Elewaut, Johannes T. Brouwer, Hubert G.M. Niesters, Solko W. Schalm, Geert Maertens, Geert Leroux-Roels, Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers, Journal of Medical Virology, 2000, 60, 2
  63. 63
    Masao Omata, Yasushi Shiratori, Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C, Journal of Gastroenterology and Hepatology, 2000, 15,
  64. 64
    V. Meier, S. Mihm, G. Ramadori, MxA gene expression in peripheral blood mononuclear cells from patients infected chronically with hepatitis C virus treated with interferon-α, Journal of Medical Virology, 2000, 62, 3
  65. 65
    Magda Guilera, Xavier Forns, Xavier Torras, Jaime Enríquez, Susana Coll, Ricard Solà, Rosa Morillas, Ramón Planas, Sergi Ampurdanès, Marta Soler, Josep Costa, Juan C Sáiz, José M Sánchez-Tapias, Juan Rodés, Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C, Journal of Hepatology, 2000, 33, 1, 135

    CrossRef

  66. 66
    Yasushi Shiratori, Masao Omata, Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course?, Journal of Gastroenterology and Hepatology, 2000, 15,
  67. 67
    Toshihiro Okamoto, The protective effect of glycyrrhizin on anti-Fas antibody-induced hepatitis in mice, European Journal of Pharmacology, 2000, 387, 2, 229

    CrossRef

  68. 68
    Mike Flint, Jane A. McKeating, The role of the hepatitis C virus glycoproteins in infection, Reviews in Medical Virology, 2000, 10, 2
  69. 69
    O. Lo Iacono, M. Fernández Bermejo, Tratamiento de las hepatitis crónicas víricas, Medicine - Programa de Formación Médica Continuada Acreditado, 2000, 8, 13, 686

    CrossRef

  70. 70
    Daniel A. Carrasco, Catherine Newman, Stephen K. Tyring, Treatment of viral hepatitis, Dermatologic Therapy, 2000, 13, 3
  71. 71
    Jean-Michel Pawlotsky, Hepatitis C, 2000,

    CrossRef

  72. 72
    John G. McHutchison, Jay H. Hoofnagle, Hepatitis C, 2000,

    CrossRef

  73. 73
    Stefan Zeuzem, Uwe Hopf, Vicente Carreno, Moisés Diago, Mitchell Shiffman, Stefan Grüne, Francis J. Dudley, Ashok Rakhit, Karen Rittweger, Sing Hiem Yap, Raymond S. Koff, Howard C. Thomas, A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C, Hepatology, 1999, 29, 4
  74. 74
    Stephen J. Polyak, Denise M. Paschal, Susan McArdle, Michael J. Jr., Darius Moradpour, David R. Gretch, Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication, Hepatology, 1999, 29, 4
  75. 75
    Calogero Cammà, Marco Giunta, Liliana Chemello, Alfredo Alberti, Hidenori Toyoda, Christian Trepo, Patrick Marcellin, Friederike Zahm, Solko Schalm, Antonio Craxì, Chronic hepatitis C: Interferon retreatment of relapsers. A meta-analysis of individual patient data, Hepatology, 1999, 30, 3
  76. 76
    Thomas M. Shehab, Seema S. Sonnad, Mark Jeffries, Naresh Gunaratnum, Anna S. Lok, Current practice patterns of primary care physicians in the management of patients with hepatitis C, Hepatology, 1999, 30, 3
  77. 77
    Antonio Craxï, Calogero Cammà, Marco Giunta, Definition of response to antiviral therapy in chronic hepatitis C, Journal of Hepatology, 1999, 31, 160

    CrossRef

  78. 78
    Francesco Negro, Krzysztof Krawczynski, Rafael Quadri, Laura Rubbia-Brandt, Mario Mondelli, Jean-Pierre Zarski, Antoine Hadengue, Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reversetranscriptase polymerase chain reaction, Hepatology, 1999, 29, 2
  79. 79
    Johannes T. Brouwer, Bettina E. Hansen, Hubert G.M. Niesters, Solko W. Schalm, Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT, Journal of Hepatology, 1999, 30, 2, 192

    CrossRef

  80. 80
    Nicolaos C. Tassopoulos, Riccardo Volpes, Giuseppe Pastore, Jenny Heathcote, Maria Buti, Robert D. Goldin, Sasha Hawley, Judy Barber, Lynn Condreay, D. Fraser Gray, Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB, Hepatology, 1999, 29, 3
  81. 81
    Marcelo A. Costa, Eugene R. Schiff, Hepatitis C, Current Treatment Options in Gastroenterology, 1999, 2, 6, 481

    CrossRef

  82. 82
    Hugo R Rosen, David R Gretch, Hepatitis C virus: current understanding and prospects for future therapies, Molecular Medicine Today, 1999, 5, 9, 393

    CrossRef

  83. 83
    Jijy Mathai, Katsuhiro Shimoda, Barbara F. Banner, Masaki Mori, Herbert L. Bonkovsky, Graham F. Barnard, IFN-alpha Receptor mRNA Expression in a United States Sample with Predominantly Genotype 1a/I Chronic Hepatitis C Liver Biopsies Correlates with Response to IFN Therapy, Journal of Interferon & Cytokine Research, 1999, 19, 9, 1011

    CrossRef

  84. 84
    Michael Trauner, Peter Fickert, Rudolf E Stauber, Inflammation-induced cholestasis, Journal of Gastroenterology and Hepatology, 1999, 14, 10
  85. 85
    Mayte Pérez-Olmeda, Juan González, Javier García-Samaniego, José Ramón Arribas, Jose María Peña, Vincent Soriano, Interferon Plus Ribavirin in HIV-Infected Patients With Chronic Hepatitis C, JAIDS Journal of Acquired Immune Deficiency Syndromes, 1999, 22, 3, 308

    CrossRef

  86. 86
    Mayte Pérez-Olmeda, Juan González, Javier García-Samaniego, José Ramón Arribas, Jose María Peña, Vincent Soriano, Interferon Plus Ribavirin in HIV-Infected Patients With Chronic Hepatitis C, Journal of Acquired Immune Deficiency Syndromes, 1999, 22, 3, 308

    CrossRef

  87. 87
    Peter Waldron, Interferon treatment of chronic active hepatitis C during therapy of acute lymphoblastic leukemia, American Journal of Hematology, 1999, 61, 2
  88. 88
    Olle Reichard, Hans Glaumann, Aril Frydén, Gunnar Norkrans, Rune Wejstål, Ola Weiland, Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon, Journal of Hepatology, 1999, 30, 5, 783

    CrossRef

  89. 89
    Pasqualina Pensati, Raffaele Iorio, Salvatore Botta, Concetta Tuccillo, Sara Donetto, Pietro Vajro, Giuseppina Ciarlo, Angela Vegnente, Low virological response to interferon in children with chronic hepatitis C, Journal of Hepatology, 1999, 31, 4, 604

    CrossRef

  90. 90
    R. De Francesco, A. Pessi, C. Steinkühler, Mechanisms of hepatitis C virus NS3 proteinase inhibitors, Journal of Viral Hepatitis, 1999, 6,
    Direct Link:
  91. 91
    Aijaz Ahmed, Emmet B. Keeffe, OVERVIEW OF INTERFERON THERAPY FOR CHRONIC HEPATITIS C, Clinics in Liver Disease, 1999, 3, 4, 757

    CrossRef

  92. 92
    Stephen A. Villano, David Vlahov, Kenrad E. Nelson, Sylvia Cohn, David L. Thomas, Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection, Hepatology, 1999, 29, 3
  93. 93
    Nieves Ibarrola, José A. Moreno-Monteagudo, Margarita Sáiz, Carmelo García-Monzón, Francisco Sobrino, Luisa García-Buey, Oreste Lo Iacono, Ricardo Moreno-Otero, Encarnación Martínez-Salas, Response to retreatment with interferon-? plus ribavirin in chronic hepatitis C patients is independent of the NS5A gene nucleotide sequence, The American Journal of Gastroenterology, 1999, 94, 9, 2487

    CrossRef

  94. 94
    U. Dutta, K. Byth, J. Kench, M. H. Khan, S. A. Coverdale, M. Weltman, R. Lin, C. Liddle, G. C. Farrell, Risk factors for development of hepatocellular carcinoma among Australians with hepatitis C: a case-control study, Australian and New Zealand Journal of Medicine, 1999, 29, 3
  95. 95
    Nobuhiko Higashi, Makoto Nakamuta, Kenta Motomura, Munechika Enjoji, Hironori Sakai, Hajime Nawata, Serum level of interleukin-4 is a possible marker of therapeutic response to interferon treatment in patients with chronic hepatitis C, Journal of Hepatology, 1999, 31, 2, 383

    CrossRef

  96. 96
    Ke-Qin Hu, Myron J. Tong, The long-term outcomes of patients with compensated hepatitis C virus–related cirrhosis and history of parenteral exposure in the united states, Hepatology, 1999, 29, 4
  97. 97
    J. M. Pawlotsky, G. Germanidis, The non-structural 5A protein of hepatitis C virus, Journal of Viral Hepatitis, 1999, 6, 5
    Direct Link:
  98. 98
    R. Bartenschlager, The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy, Journal of Viral Hepatitis, 1999, 6, 3
  99. 99
    Karen L. Lindsay, Treatment of chronic hepatitis C: comparative virologic response rates among the different interferons, Journal of Hepatology, 1999, 31, 232

    CrossRef

  100. 100
    Aijaz Ahmed, Emmet Keeffe, Treatment strategies for chronic hepatitis C: Update since the 1997 National Institutes of Health Consensus Development Conference, Journal of Gastroenterology and Hepatology, 1999, 14, 5s
  101. 101
    Heiner Wedemeyer, Wolfgang H. Caselmann, Michael P. Manns, Combination therapy of chronic hepatitis C: an important step but not the final goal!, Journal of Hepatology, 1998, 29, 6, 1010

    CrossRef

  102. 102
    Warren N. Schmidt, Ping Wu, Donna Brashear, Donna Klinzman, Mary Jeanne Phillips, Douglas R. LaBrecque, Jack T. Stapleton, Effect of interferon therapy on hepatitis C virus RNA in whole blood, plasma, and peripheral blood mononuclear cells, Hepatology, 1998, 28, 4
  103. 103
    Johannes T. Brouwer, Frederik Nevens, Bernhard Kleter, Andre Elewaut, Michael Alder, Reginald Brenard, Rob A.F.M. Chamuleau, Peter P. Michielsen, Jean Pirotte, Marc L. Hautekeete, Joseph Weber, Nadine Bourgeois, Bettina E. Hansen, Carolien M. Bronkhorst, Fibo J.W. ten Kate, Rudolf A. Heijtink, Johan Fevery, Solko W. Schalm, Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients, Journal of Hepatology, 1998, 28, 6, 951

    CrossRef

  104. 104
    Ola Weiland, FGFR2 mutations and acne Can HCV infection be cleared?, The Lancet, 1998, 352, 9129, 669

    CrossRef

  105. 105
    Ulrich Spengler, Jürgen K. Rockstroh, Hepatitis C in the patient with human immunodeficiency virus infection, Journal of Hepatology, 1998, 29, 6, 1023

    CrossRef

  106. 106
    Ann D Kwong, Joseph L Kim, Govinda Rao, Dasa Lipovsek, Scott A Raybuck, Hepatitis C virus NS3/4A protease, Antiviral Research, 1998, 40, 1-2, 1

    CrossRef

  107. 107
    Paul L. F. Giangrande, HEPATITIS IN HAEMOPHILIA, British Journal of Haematology, 1998, 103, 1
  108. 108
    Gary L. Davis, Rafael Esteban-Mur, Vinod Rustgi, John Hoefs, Stuart C. Gordon, Christian Trepo, Mitchell L. Shiffman, Stefan Zeuzem, Antonio Craxi, Mei-Hsiu Ling, Janice Albrecht, Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C, New England Journal of Medicine, 1998, 339, 21, 1493

    CrossRef

  109. 109
    S. Moscarella, G. Buzzelli, R. G. Romanelli, M. Monti, C. Giannini, G. Careccia, E. M. Marrocchi, A. L. Zignegoy, Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results, Liver, 1998, 18, 5
  110. 110
    Thierry Poynard, Patrick Marcellin, Samuel S Lee, Christian Niederau, Gerald S Minuk, Gaetano Ideo, Vincent Bain, Jenny Heathcote, Stefan Zeuzem, Christian Trepo, Janice Albrecht, Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus, The Lancet, 1998, 352, 9138, 1426

    CrossRef

  111. 111
    CARLO FABRIS, GIORGIO SOARDO, EDMONDO FALLETI, PIERLUIGI TONIUTTO, DANIELA VITULLI, EDDA FEDERICO, MONICA DEL FORNO, MARTINA MATTIUZZO, FABIO GONANO, MARIO PIRISI, Relationship Among Hepatic Inflammatory Changes, Circulating Levels of Cytokines, and Response to IFN-α in Chronic Hepatitis C, Journal of Interferon & Cytokine Research, 1998, 18, 9, 705

    CrossRef

  112. 112
    C. A. Lee, C. M. Kessler, D. Varon, U. Martinowitz, M. Heim, G. M. DUSHEIKO, Therapy for chronic hepatitis B and C infection in haemophilia, Haemophilia, 1998, 4, 4